Stephen Rocamboli - 10 Mar 2023 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Stephen Rocamboli, by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 10 Mar 2023
Net transactions value: +$10,432
Form type: 4
Filing time: 13 Mar 2023, 16:22:37 UTC
Previous filing: 30 Dec 2022
Next filing: 11 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TFFP	Common Stock	Purchase	$10,432	+13,000	+433%	$0.8025	16,000	10 Mar 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported shares were purchased in the open market in multiple transactions at prices ranging from $0.8025 to $0.8026. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).

Content

The reported shares were purchased in the open market in multiple transactions at prices ranging from $0.8025 to $0.8026. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).